logo
Twitter
Discord
Email
logo
Summit Therapeutics Inc.

Summit Therapeutics Inc.

NASDAQ•SMMT
CEO: Mr. Robert W. Duggan
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2015-03-05
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.
Contact Information
601 Brickell Key Drive, Suite 1000, Miami, FL, 33131, United States
650-460-8308
www.summittxinc.com
Market Cap
$13.27B
P/E (TTM)
-14.4
40.5
Dividend Yield
--
52W High
$36.91
52W Low
$15.55
52W Range
11%
Rank61Top 80.3%
2.4
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.4 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024

Financial Dashboard

Q3 2025 Data

Revenue

$0.00+0.00%
4-Quarter Trend

EPS

-$0.31+287.50%
4-Quarter Trend

FCF

-$95.09M+213.26%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Positive HARMONi Trial Results Phase III HARMONi trial showed statistically significant PFS improvement (HR 0.52) combining ivonescimab with chemotherapy.
BLA Submission Planned Q4 Company plans to submit Biologics License Application seeking approval for ivonescimab plus chemotherapy in Q4 2025.
Cash Position Significantly Increased Cash and equivalents totaled $238.9M at period end, up from $105.2M at year-end 2024, supported by financing.
R&D Costs Surge Post-Modification Nine-month R&D expenses reached $390.4M, up $291.0M, driven by performance stock option modification accounting treatment.

Risk Factors

Substantial Going Concern Doubt Cash insufficient to fund planned operations for next twelve months, raising substantial doubt about continuing operations.
Net Loss Widened Significantly Nine-month net loss increased $700.3M to $(860.4)M, reflecting heavy investment in oncology development pipeline.
Related Party Litigation Active Derivative lawsuit filed concerning December 2022 notes, asserting breach of fiduciary duty and seeking unspecified damages.
Future Financing Required Must raise additional capital to fund operations and potential $4.56B milestone payments owed under Akeso agreements.

Outlook

HARMONi-3 Cohort Analysis HARMONi-3 trial protocol amended to conduct separate PFS/OS analyses for squamous and non-squamous NSCLC cohorts.
Expanding Solid Tumor Focus Intends to explore further clinical development of ivonescimab in solid tumor settings outside current Phase III indications.
Utilizing ATM Proceeds Plans to use remaining $373.2M available under Distribution Agreement for working capital and general corporate needs.
Akeso Milestone Payments Future capital needs depend partly on potential $4.56B milestone payments owed to Akeso upon regulatory success.

Peer Comparison

Revenue (TTM)

Centene CorporationCNC
$185.86B
+14.9%
Tenet Healthcare CorporationTHC
$20.86B
-0.6%
Genmab A/SGMAB
$18.26B
-7.6%

Gross Margin (Latest Quarter)

Royalty Pharma plcRPRX
100.0%
+0.0pp
Ionis Pharmaceuticals, Inc.IONS
98.5%
-0.7pp
BridgeBio Pharma, Inc.BBIO
94.6%
+16.5pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
UTHR$23.10B17.818.8%0.0%
INCY$20.16B16.929.8%0.6%
GMAB$19.95B14.824.7%2.0%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Feb 23, 2026
|
EPS:-$0.22
|
Revenue:-
Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Oct 20, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.31+287.5%
    N/A

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 11, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.76+791.0%
    N/A

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 1, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.09+37.6%
    N/A

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 24, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.31+68.7%
    N/A

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Oct 30, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.08+166.7%
    N/A

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 6, 2024|
    Revenue: $0.00-100.0%
    |
    EPS: $-0.09+304.3%
    N/A

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 1, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.06-95.7%
    N/A

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 20, 2024|
    Revenue: $0.00-100.0%
    |
    EPS: $-0.99-141.5%
    N/A